CLINICAL TRIAL

FOLLOW UP VISIT-TELEMEDICINE for Prostate Cancer

Recruiting · 18+ · All Sexes · Boston, MA

This study is evaluating whether telemedicine visits are as effective as face-to-face visits.

See full description

About the trial for Prostate Cancer

Eligible Conditions
Prostatic Neoplasms · Breast Cancer · Prostate Cancer · Preference, Patient · Patient Engagement · Satisfaction, Patient

Treatment Groups

This trial involves 2 different treatments. FOLLOW UP VISIT-TELEMEDICINE is the primary treatment being studied. Participants will be divided into 2 treatment groups. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Experimental Group 1
FOLLOW UP VISIT-TELEMEDICINE
BEHAVIORAL
Experimental Group 2
FOLLOW UP VISIT-FACE TO FACE
BEHAVIORAL

Eligibility

This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Participant is on a surveillance follow up visit schedule occurring at every three to seven month intervals
Age ≥ 18 years
For breast cancer participants: Early-stage breast cancer defined as Stages I-IIIA at diagnosis or localized prostate cancer defined as Stages I-III
For breast cancer participants: participant has completed definitive treatment for early stage breast cancer including surgery, radiation, chemotherapy, anti-HER2 antibody treatment. Participant may or may not be taking oral anti-estrogen treatment such as tamoxifen or an aromatase inhibitor For prostate cancer participants: participant is on active surveillance or has undergone definitive surgery for localized prostate cancer
Willingness and ability to use Patient Gateway portal
Participant has access to an electronic device that can support a video and audio virtual visit platform (for example, laptop computer, desktop computer, smart phone)
Participants can be women or men
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: Up to 6 months
Screening: ~3 weeks
Treatment: Varies
Reporting: Up to 6 months
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: Up to 6 months.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether FOLLOW UP VISIT-TELEMEDICINE will improve 1 primary outcome and 6 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Two weeks after study visit.

Health system use Comparison
TWO WEEKS AFTER STUDY VISIT
Compare participant health system use relating to cancer diagnosis within two weeks after study visit
TWO WEEKS AFTER STUDY VISIT
Clinician Preference
UP TO 6 MONTHS
Assessing clinician preference regarding the appropriate use of telemedicine visits for the follow-up of early stage cancer patients who have completed early active therapy (e.g., surgery, radiation and/or chemotherapy) or are under surveillance
UP TO 6 MONTHS
Clinician Experience Comparison
UP TO 6 MONTHS
Compare the clinician experience with Telemedicine (TM) versus Face to Face (F2F) for a one-time surveillance follow up visit for breast or prostate cancer care
UP TO 6 MONTHS
Symptom severity-prostate cancer patients Comparison
UP TO 6 MONTHS
Compare patient reported erectile dysfunction and urinary symptoms after undergoing radical prostatectomy between patients who have a TM follow up visit vs. a F2F follow up visit
UP TO 6 MONTHS
Indirect Health Care Costs Comparison
UP TO 6 MONTHS
Compare patient reported indirect healthcare costs for Telemedicine (TM) versus Face to Face (F2F) follow up visits:
UP TO 6 MONTHS
Patient Experience Comparison
UP TO 6 MONTHS
Compare early-stage breast and early stage prostate cancer patients' experiences with a one-time Telemedicine (TM) versus Face to Face (F2F) follow up visit for routine oncologic surveillance
UP TO 6 MONTHS
See More

Who is running the study

Principal Investigator
E. S.
Eleni Stavrou, Principal Investigator
Dana-Farber Cancer Institute

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What causes prostate cancer?

Results from a recent clinical trial suggest that the substantial increase in incidence of prostate cancer is unlikely to be due to increased exposure to environmental agents such as tobacco smoke, ionizing radiation, and/or occupational carcinogens. Rather, our results point toward an association between increased consumption of red meat and increased risk of prostate cancer and support the hypothesis that obesity in women and lack of physical activity are risk factors for developing prostate cancer.

Anonymous Patient Answer

Does prostate cancer run in families?

Results from a recent paper suggest that the familial aggregation of prostate cancer does not appear to be due to an altered predisposition to prostate cancer in males who have a first degree relative with prostate cancer.

Anonymous Patient Answer

How serious can prostate cancer be?

Prostate cancer is inherently more dangerous than many other cancers due to its tendency to spread before it can be detected. The use of aggressive diagnostic measures, including repeat transrectal ultrasound examinations and prostate biopsy, can reduce this inherent danger by detecting and treating prostate cancer early on so that it does not become life-threatening.

Anonymous Patient Answer

How many people get prostate cancer a year in the United States?

The data suggest that there are more than 4 million men at increased risk of developing PCa. Results from a recent paper provides information needed to develop and implement programs to identify high-risk men who should be offered prostate-specific antigen screening.

Anonymous Patient Answer

How does follow up visit-telemedicine work?

Telemedicine can be an effective tool in following up patients who have had biopsy and are receiving active treatment. Telemedicine can also be used to help manage other follow-up visits.

Anonymous Patient Answer

What is follow up visit-telemedicine?

Telemedicine can be an effective tool for providing biologic information and therapies, and follow-up visits can be accomplished within an outpatient setting. Further studies are needed to determine whether telemedicine can improve patient satisfaction and outcomes of care.

Anonymous Patient Answer

Who should consider clinical trials for prostate cancer?

A high proportion of patients offered to participate in clinical trials for prostate cancer were not enrolled, especially among younger, less educated, and non-treatment seeking men. Findings from a recent study suggest that recruiting men into clinical trials might be improved by offering trial information by means of the Internet, print, or both.

Anonymous Patient Answer

What is prostate cancer?

To diagnose [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), a definitive diagnosis of histological grade must be made (for example, Gleason score 7 or higher) and a biopsy must be done to confirm this diagnosis. If a biopsy cannot be done, the patient should have a second opinion before any treatment is started. A great deal of uncertainty still exists about what constitutes optimal treatment for prostate cancer. Although prostate cancer is treated by surgery, radiation therapy, hormonal therapy, chemotherapy and targeted therapies, none of these approaches are curative. Therefore, the management of prostate cancer remains challenging. The primary goal of prostate cancer treatment is to control symptoms and prolong life. The most effective way to do this is to reduce the volume of the prostate.

Anonymous Patient Answer

What are the chances of developing prostate cancer?

As we age, the probability of developing prostate cancer at any time point decreases exponentially. Age at diagnosis influences prognosis where early prostate cancers have an excellent outcome while late stage disease results in poor outcomes. On average only 1200 men developed prostate cancer between 1981 and 1990. Older men should be encouraged to participate in prostate cancer screening programs.

Anonymous Patient Answer

Has follow up visit-telemedicine proven to be more effective than a placebo?

Recent findings revealed no difference in efficiency between regular follow-up visits at clinic visits and telemedicine sessions for prostate cancer detection. The study was limited by its small size.

Anonymous Patient Answer

Have there been any new discoveries for treating prostate cancer?

The hormone ablation therapy was reported to be effective at reducing the progression of prostate cancer in trials but the effectiveness of ablation therapy for women with advanced prostate cancer remains unproven. The use of antiandrogens has been shown to be effective in treating former untreated men who present with HRPC. In addition, some studies suggest that adjuvant radiotherapy may decrease prostate cancer mortality. However, the efficacy of radiation therapy in all stages of prostate cancer still remains unknown. More research is needed to determine treatment modalities that maximize outcomes in HRPC.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Prostate Cancer by sharing your contact details with the study coordinator.